RoboticFirms

Article • surgical-robots

Vicarious Surgical Board Plans Liquidation of Surgical Robotics Developer

ByAyshathul Mushrifa

WALTHAM, Mass. — Vicarious Surgical's board of directors has proposed shutting down and liquidating the company, asking shareholders to approve a formal dissolution plan during a special meeting scheduled for July 21, 2026.

The Massachusetts-based medical robotics developer, known for creating a miniature robotic system designed for minimally invasive procedures, stated that recurring operating losses and severely limited cash resources have made it impossible to continue as a going concern.

The company reported just $3.7 million in cash, cash equivalents, and short-term investments as of March 31, 2026, balanced against $9 million in total liabilities.

In an official securities filing, the company warned that based upon outstanding liabilities, it is unlikely investors will receive any distribution. Vicarious Surgical had developed a highly compact soft-tissue surgical robot engineered to operate entirely through a single incision smaller than a dime, specifically targeting applications like hernia repair.

However, commercialization proved capital-intensive, leading to steep deficits including a $7.3 million net loss for the first quarter of 2026.

Management detailed their exhaustive efforts to preserve operations, noting they have been unable to secure additional equity, debt, or financing and have been unsuccessful in attracting a buyer. If the liquidation plan achieves a majority vote at the upcoming special session, the board will hand over asset distribution to a selected assignee outside of federal bankruptcy courts.

The vote is highly likely to pass, as company executives and directors control roughly 55% of the total voting power. The dissolution strategy follows the recent departure of CFO Sarah Romano, who tendered her resignation to join SS Innovations.

The company currently operates out of a 42,000-square-foot facility in Waltham with 26 remaining employees across research, quality assurance, and administrative divisions, with all operations expected to cease immediately upon execution.